reason report
lower tax rate push outlook higher thv sale too-
bottom line ew share like trade today reaction
disappoint thv transcathet heart valv sale rel
high expect head print ultim
think tavr transcathet aortic valv replac growth
stori play unchang -- like
conserv -- view continu believ
ramp less sick patient popul -- current intermedi
risk eventu low risk begin late next year -- like
continu volatil less consist
saw high risk/inoper ew still well-posit deliv
premium growth within mid-to-larg cap med-tech univers
thu deserv trade premium less consist
beat potenti tap possibl deceler tavr growth
-- least see low risk data --
premium could narrow argu ew abl
maintain current multipl less clear upsid
yesterday market close ew report adjust
sale y/i ex fx total sale
came ahead us consensu thv sale fell
consensu us global thv sale deliv
anoth solid double-digit growth quarter -- continu
manag guid toward high end annual
guidanc rang -- modest sale miss could weigh ew share
given repres first quarter global tavr
growth sinc manag call share loss ou
someth believ revers current centera launch
ew also announc complic earli harpoon patient --
one compani mitral program -- could delay expect
price-to-earnings multipl ep estim pt assum
ew maintain current multipl ep also think
ew market-lead posit highli under-penetrated total
address market justifi compani premium valuat rel
rest large-cap med-tech group
outlook ep estim move higher reflect
greater tax benefit sale estim move slightli
lower y/i y/i vs
previous lower thv sale royalti realli
drive lion share move estim ep estim
previous reflect
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
compani inform leerink partner llc research
revenu mm non-gaap dilut adjust ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul current intermedi risk potenti
low risk beyond might occur slower pace already-elev investor
expect continu believ intermedi risk indic repres massiv
increment market opportun estim intermedi risk doubl
address patient popul also believ ramp patient may slower
saw inoper high risk given linger question around tavr
durabl longer term need seemingli intens market develop effort
drive referr particularli younger less sick portion intermedi risk patient
popul potenti increas surgeon pushback less sick patient popul
heart member ramp effort preserv surgic busi
ultim believ global tavr market exceed line ew
guidanc new indic come on-line low risk eventu asymptomat
near-to-medium term ew still beat rais stori base earli read
intermedi risk adopt ramp think beat next month may
smaller tougher come last two year particularli light
competit launch addit steadier intermedi risk ramp vs step function chang
growth street seem expect share current trade earn
becom increasingli difficult argu meaning multipl expans leav us
upsid current level base estim
price target appli price-to-earnings multipl ep estim
pt assum ew maintain current multipl ep also think ew
market-lead posit highli under-penetrated total address market justifi
compani premium valuat rel rest large-cap med-tech group
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
dollar million except per share data
good sold
research develop expens
incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
ew initi trial low-risk patient earli enrol trial
began random trail studi sapien low risk patient
enrol expect continu risk defin patient
st score ew see next step expans market intermedi risk
posit trial enrol year age limit also remov protocol
 oct trial tooker littl longer start-up phase ew continu expect
earn call site engag
 octob compani expect enrol complet year end
 decemb main studi enrol complet ct sub-studi continu enrol
 april ew receiv approv limit continu access protocol cap
allow on-going treatment select clinic site limit number low-risk patient
clinic trial prospect random control multi-cent studi patient
random receiv either transcathet aortic valv replac tavr edward
sapien thv clinic surveil patient stratifi whether abl
perform treadmil stress test patient posit stress test follow
registri collect data subsequ treatment mortal applic
 februari ew expect result present
 decemb ew expect fda approv late
ew plan enrol patient year older
 januari receiv fda approv patient across center begin enrol later
 octob trial continu enrol
sapien ultra new deliveri system expect better command
system new ultra system featur on-balloon deliveri system nextgener sheath
-a decemb ew expect new ultra system featur on-balloon deliveri system
nextgener sheath technolog receiv ce mark end earli launch
 april ew conduct small clinic trial sapien ultra system supplement
european regulatori submiss unanticip start process reflect
evolv european regulatori climat manag expect complet enrol patient
quarter receiv ce mark approv ultra system second half
ce mark eu launch
centera centera ew self-
expand system
deliveri cathet motor
late decemb compani expect approv late
-ew present centera self-expend clinic data pcr earli
-ew present posit clinic data london valv confer late
 decemb ew expect ce mark end
 ce mark receiv februari
 decemb pivot trial plan
 receiv approv pivot trial
-ew expect begin enrol single-arm trial studi nearli patient
one year endpoint includ enrol patient bicuspid sub studi
-a januari ew recent paus enrol clinic trial perform design
valid test featur valv ew see posit result test clinic trial
expect resum enrol paus also postpon start ce mark trial
 juli ew expect resum enrol year
 octob ew decid includ number signific enhanc valv
serv broader group patient
 decemb expect enrol resum enhanc made
octob ew decid commerci valv system incorpor number
enhanc ew current ce mark expect
 decemb slimmer devic profil new transsapi deliveri system expect
introduc
 earli feasibl studi cardiaq-edward transcathet mitral valv
tmv treatment moder sever mitral regurgit
on-go ew plan enrol multi-cent prospect single-arm non-random studi
ew aleadi ce mark product europ commerci launch on-go
 record commer sale europ
 present year follow-up data tct
 ide trial activ trial prospect random multicent trial patient
clinic signific function mitral regurgit random receiv either
transcathet mitral valv repair edward cardioband system plu guidelin direct
medic therapi gdmt gdmt alon patient seen follow-up visit discharg
day month annual year
on-go ew plan enrol patient
 decemb publish posit data lancet present month result
specif target leaflet repair
treat broad spectrum mitral
purpos studi assess safeti perform clinic outcom
edward pascal transcathet mitral valv repair tmvr multi-cent multi-
nation prospect singl arm safeti perform clinic outcom studi
edward announc structur up-front invest harpoon pioneer beating-heart repair
degen mitral regurgit dmr exclus option acquir
compani dec edward announc acquisit harpoon medic inc
million cash potenti million pre-specifi milestone-driven
payment next year
cardioband activ enrol ce mark trial expand indic tricuspid patient
target ce mark approv
 earli feasibl studi set start
ce mark eu launch
ew plan enrol patient earli feasibl studi
 octob ew begun enrol ce mark trial expect expand trial
multipl center remaind year
 februari ew expect complet enrol
 decemb expect product launch
 februari ew track initi pascal trial
 decemb ce mark expect year end earli
 april ew learn complic three treat earli clinic studi
may influenc time commerci launch
 februari ew expect european launch
complet juli ew complet enrol ce mark trial cardioband tricuspid physician
 patient day earli readout present tct demonstr high procedur success
 decemb expect eu introduct late
 februari ew receiv approv begin earli feasibl studi work
activ center
ew plan enrol patient
updat expect tct medic confer octob ew investor confer decemb
on-go ew plan enrol patient
 earli feasibl studi edward forma tricuspid transcathet repair
spacer trial repair
edward tricuspid
purpos studi assess safeti devic perform edward
tricuspid transcathet repair system patient clinic signific symptomat
tricuspid regurgit high surgic risk standard tricuspid repair/replac
studi multi-cent intern prospect singl arm safeti studi enrol subject
assess clinic follow-up month month year annual year post
patient enrol
primari endpoint studi assess mortal cardiac treat cohort day
compar literatur deriv perform goal base high-risk surgic outcom tricuspid
sg sale sale
high end
high end
higher end
higher end
midpoint
tmtt
tmtt
tmtt
midpoint
high end
high end
high end
high end
